Growth Hormone News and Research

RSS

Growth hormone (GH) is a protein-based peptide hormone. It stimulates growth, cell reproduction and regeneration in humans and other animals. Growth hormone is a 191-amino acid, single-chain polypeptide that is synthesized, stored, and secreted by the somatotroph cells within the lateral wings of the anterior pituitary gland.

Akela to terminate lease payment agreement

Akela a leader in the development of therapeutics for the treatment of pain and its wholly owned subsidiary, PharmaForm, a leader in the contract pharmaceutical development and manufacturing business, today announced that it has reached agreement with HEP Davis Spring, L.P. to terminate its lease located at 9825 Spectrum Drive, Austin, Texas, eliminating $14,500,000 in future lease payment obligations to the Company.

17 Apr 2010

Risks and benefits of anti-aging hormones

In an editorial appearing in the Future Medicine journal Aging Health, Dr. Perls applauds the courage and example displayed by the AMA in its recently published assessment of the risks and benefits of growth hormone, testosterone, estrogen and DHEA for anti-aging.

15 Apr 2010

Researchers identify major indicator of heart failure and aortic aneurysms

Case Western Reserve University School of Medicine researchers have identified a major indicator of two deadly diseases of the heart and blood vessels: heart failure and aortic aneurysm. The absence of the Kruppel-like Factor 15, when combined with stress, leads to both heart failure and aortic aneurysms.

8 Apr 2010

NNIT selects Verizon Business to manage global communications infrastructure for Novo Nordisk

NNIT, a leading Danish IT consultancy, has chosen Verizon Business to deploy and manage a global communications infrastructure for Novo Nordisk, the global health care company. A fully managed Verizon Private IP solution will provide secure, scalable and flexible connectivity for 75 of Novo Nordisk's locations around the world, helping the company to streamline its global operations, while also realizing cost and management efficiencies.

7 Apr 2010

Cancer Prevention Coalition submits petition on imminent health hazard from hormonal meat

As reported in a March 18, New York Times editorial, "Honest Food Labels," FDA Commissioner, Margaret Hamburg, M.D., publicized letters to 17 food companies accusing them of -- "masking undesirable ingredients" -- in their products. She also emphasized the importance of "providing nutrition information that consumers can rely on."

3 Apr 2010

Minimally invasive technique holds promise for removing large brain tumors

A minimally invasive endoscopic procedure holds promise for safely removing large brain tumors from an area at the bottom of the skull, near the sinus cavities, clinical researchers at the Brain Tumor Center at the University of Cincinnati Neuroscience Institute (UCNI) at University Hospital have found.

2 Apr 2010

Patients switching to Victoza experience further reductions in A1c and weight loss

Diabetes Care published online the results of the Novo Nordisk LEAD™ 6 extension study, which evaluated the efficacy and safety of switching from exenatide, which is taken twice a day, to once-daily Victoza®. Results show that when added to oral antidiabetes drugs, patients who switched from exenatide to Victoza experienced further reductions in A1c and weight loss.

31 Mar 2010

Access Pharmaceuticals, bioRASI sign collaborative agreement to develop Cobalamin oral insulin product

ACCESS PHARMACEUTICALS, INC. signed a collaborative development agreement with bioRASI, LLC, a full-service global CRO specializing in the accelerated development of novel therapeutics, to facilitate clinical development for its Cobalamin™-based oral insulin and other Cobalamin-based products.

31 Mar 2010

Novo Nordisk BlueSheet launched to provide information on diabetes and chronic disease

Novo Nordisk, a global healthcare company and leader in diabetes care, today announced the launch of the Novo Nordisk BlueSheet, a resource for information on diabetes and chronic disease, highlighting key issues in diabetes prevention, detection, treatment and care.

30 Mar 2010

Æterna Zentaris announces 2009 financial and operating results

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported financial and operating results as at and for the fourth quarter and the full year ended December 31, 2009.

24 Mar 2010

Akela Pharma files restated Management Discussion and Analysis for 2008 fiscal year

Akela Pharma, Inc., a leader in the development of therapeutics for the treatment of pain, and the company's wholly owned subsidiary, PharmaForm, today that it has today filed a restated Management Discussion and Analysis ("MD&A) for the fiscal year ended 2008.

20 Mar 2010

Novo Nordisk awarded funds to support diabetes summer camps nationwide

Novo Nordisk Inc., a world leader in diabetes care, announced that it has awarded funds to support scholarships and capital improvements to diabetes summer camps at fifteen locations nationwide. In support of their dedication to meeting the needs of children with diabetes, the grants will help the camps provide financial assistance programs to campers and improve facilities for the campers' use.

From Novo Nordisk 16 Mar 2010

Ipsen commences dosing in two BIM 23A760 phase II studies for neuroendocrine tumors and acromegaly

Ipsen announced today the initiation of dosing in two phase II clinical studies to evaluate efficacy and safety of BIM 23A760 in two groups of patients, one suffering from carcinoid syndrome due to neuroendocrine tumors, the other from acromegaly.

15 Mar 2010

CBio recruits 75th patient into XToll phase II clinical trial, achieves milestone under agreement with Novo Nordisk

Australian drug development company CBio Limited today announced the achievement of a clinical trial milestone under its option agreement with global pharmaceutical leader Novo Nordisk A/S. The agreement relates to the development of XToll, the potential new-generation drug therapy which could provide safer and more effective treatment of autoimmune diseases such as rheumatoid arthritis (RA).

12 Mar 2010

Independently-conducted studies confirm significant bioavailability of orally delivered insulin

ACCESS PHARMACEUTICALS, INC. announced that it has received reports of significant bioavailability of orally delivered insulin in two independently-conducted animal studies. The studies, which confirm earlier findings, were performed as part of on-going work with commercial collaborators that are evaluating Access' Cobalamin™ Oral Drug Delivery Technology.

12 Mar 2010

Diplomat Specialty Pharmacy to help patients obtain financial assistance to purchase life-saving drugs

Diplomat Specialty Pharmacy, the nation's largest privately held specialty pharmacy company, is on a mission to help patients obtain the financial assistance they need to purchase life-saving drugs for such illnesses as cancer, HIV/AIDS and Hepatitis C, as well as drugs for Multiple Sclerosis, kidney disease and other chronic conditions.

4 Mar 2010

Novo Nordisk awarded contract by VA as primary source provider of insulin

Novo Nordisk, a global healthcare company and leader in diabetes care, announced it has been awarded a contract by the U.S. Department of Veterans Affairs as the primary source provider of insulin. The one year contract began on March 1, 2010 and the VA has the option to renew the contract annually for up to an additional four years.

From Novo Nordisk 3 Mar 2010

Antares Pharma completes enrollment in Phase 3 clinical trial of Anturol for OAB

Antares Pharma, Inc. announced today that it has completed enrollment in the double-blind portion of the Company’s Phase 3 clinical trial of Anturol™, its transdermal oxybutynin ATD™ gel for the treatment of overactive bladder (OAB). Top line data from this pivotal trial, which is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA), is expected in the third quarter of this year.

2 Mar 2010

High levels of anti-aging hormone may increase cancer mortality in older men

According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), older men with high levels of the hormone IGF-I (insulin-like growth factor 1) are at increased risk of cancer death, independent of age, lifestyle and cancer history.